Status:
COMPLETED
Effectiveness of Antidepressant Treatment for Depression in People With Parkinson's Disease
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depressive Disorder
Parkinson Disease
Eligibility:
All Genders
30-79 years
Phase:
PHASE4
Brief Summary
This study will evaluate the effectiveness of atomoxetine in reducing symptoms of depression in people with Parkinson's disease.
Detailed Description
Depression is a serious medical condition that affects people's thoughts, feelings, and ability to function in everyday life. Depression can happen to anyone, but it is more of a risk in people with P...
Eligibility Criteria
Inclusion
- Diagnosis of idiopathic Parkinson's disease
- IDS score greater than 21
- Mini-Mental State Examination (MMSE) score greater than 15
Exclusion
- Recent deep brain stimulation
- Currently participating in an antidepressant trial at a less than adequate dose and duration
- Severe depression or depression with suicide ideation
- History of liver toxicity
- Unstable medical disease or comorbid psychiatric disease
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00304161
Start Date
July 1 2004
End Date
December 1 2008
Last Update
January 30 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Philadelphia Veterans Affairs Medical Center
Philadelphia, Pennsylvania, United States, 19104
2
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104